Ongoing clinical trials in ovarian cancer are evaluating inhibitors of multiple molecular pathways such as PI3K/AKT, the mTOR pathway, angiogenesis, the MAPK pathway, and the HER/EGFR pathway [27,28]. Here, MTOR is linked to ovarian carcinoma.